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Abstract
Background: Compulsory submission of a checklist from the relevant reporting guideline is one of the most
widespread journal requirements aiming to improve completeness of reporting. However, the current suboptimal
levels of adherence to reporting guidelines observed in the literature may indicate that this journal policy is not
having a significant effect.
Findings: We explored whether authors provided the appropriate CONSORT checklist extension for their study and
whether there were inconsistencies between what authors claimed on the submitted checklist and what was
actually reported in the published paper. We randomly selected 12 randomized trials from three journals that
provide the originally submitted checklist and analyzed six core CONSORT items. Only one paper used the
appropriate checklist extension and had no inconsistencies between what was claimed in the submitted checklist
and what was reported in the published paper.
Conclusion: Journals should take further actions to take full advantage of the requirement for the submission of
fulfilled CONSORT checklists, thus ensuring that these checklists reflect what is reported in the manuscript.
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Background
Completeness of reporting is a critical issue in health re-
search. It enhances the transparency of research
methods and findings, thus promoting their credibility
and reproducibility. In an attempt to improve complete-
ness of reporting, several reporting guidelines for differ-
ent study designs and clinical areas were developed in
the last two decades [1]. The Consolidated Standards of
Reporting Trials (CONSORT), was created in 1996 to
help authors report the methods and findings of ran-
domized trials [2]. It has been revised and updated twice
[3, 4]. ‘Endorsement’ of CONSORT by medical journals
has been one of the most widespread actions imple-
mented to improve the levels of completeness of report-
ing of randomized trials. It is defined as any of the
following situations: (a) journal editorial statement en-
dorsing CONSORT; (b) requirement or recommenda-
tion in journal’s instructions to authors to follow
CONSORT when preparing their manuscript; or (c) re-
quirement for authors to submit a CONSORT checklist
with their manuscript [5]. Existing evidence shows that,
despite modest improvements when CONSORT is en-
dorsed by journals, the completeness of reporting of tri-
als remains suboptimal [5].
In recent years, dozens of medical journals have opted
for policy (c) in the previous paragraph, as it has the
most potential to improve completeness of reporting. In
addition, in an effort to make the editorial process more
transparent and credible, some journals following this
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policy, such as PLoS One, BMJ Open and Trials, also
make the original CONSORT checklist submitted by the
authors accessible for their readers as supplementary
material. However, the current suboptimal levels of ad-
herence to reporting guidelines observed in the literature
across different research areas and study designs [6] may
indicate that this journal policy is not having the desired
effect. To date, there has been no investigation into
whether or not there are inconsistencies between what
authors claim to have reported in the submitted check-
list and what is actually reported in the published paper.
A number of specific study designs (such as cluster
designs) or interventions (such as non-pharmacological
interventions) have additional specific extensions [7, 8].
In the journals mentioned, authors are required to sub-
mit the CONSORT extension that applies to their study.
Thus, it is essential to assess whether authors actually
provide the appropriate extensions for their studies.
In this commentary, we explore (1) whether authors
provide the appropriate CONSORT checklist and (2)
whether there are inconsistencies between what authors
claim to have reported in the submitted checklist and
what they have actually reported in the published paper,
for those papers submitted with the appropriate check-
list. Our intention is to illustrate whether CONSORT
checklist fulfilment by authors should be considered a
guarantee that CONSORT items are effectively satisfied.
Our findings
We looked at 12 randomly selected randomized trials pub-
lished in either Trials, BMJ Open or PLoS One between 1
January 2016 and 30 June 2017 (see Additional file 1: Point
1, search strategy and study selection). We chose those
journals because they require authors to submit a
CONSORT checklist with their manuscript and make this
checklist accessible for their readers as supplementary ma-
terial. For each paper selected, we retrieved the initial
CONSORT checklist and manuscript submitted by the au-
thors. First, we independently determined whether the
CONSORT checklist originally submitted by the authors
was the appropriate extension for the study design. Then,
for papers using the appropriate checklist, we compared it
with what was actually reported in the published paper to
identify any inconsistencies (see Additional file 1: Point 2,
analysis of inconsistencies). We focused on six core CON-
SORT items of the ‘Methods’ and ‘Results’ sections: (6a)
outcomes; (8a) randomization or sequence generation; (9)
allocation concealment mechanism; (11a) blinding; (13a)
flow of participants and (13b) losses and exclusions. We
selected those items because they are essential for system-
atic reviewers to evaluate the risk of bias. For each item,
the CONSORT explanation and elaboration document [9]
was used to determine what information should be
reported.
We graded the consistency between what authors said
and what they reported for each item as follows:
 Completely consistent: There was no divergence
between what authors claimed to have reported
through the originally submitted CONSORT checklist
and what they reported in the published paper.
 Partially consistent: This may include either (a) partial
absence of relevant information that was expected to
be reported or (b) information corresponding to that
item was reported in a different part of the paper
from that specified in the checklist.
 Not consistent: Authors claimed to have reported
that item through the CONSORT checklist but did
not adequately report the information in the
published paper.
From the 12 randomly selected randomized trials, the
standard CONSORT checklist was appropriate for six pa-
pers (four of which were standard parallel trials covered by
CONSORT and two of which were crossover trials, for
which there is not an extension yet). The other six re-
quired CONSORT extensions (for cluster trials, three; for
pragmatic trials, two; and for non-pharmacological inter-
ventions, one) but authors did not use them in any case,
despite the extensions being available at the time of sub-
mission. The aforementioned extensions were published
between 2008 and 2012 [7, 8, 10], yet the six papers requir-
ing their uptake were all submitted later than May 2015.
For the six papers for which an appropriate CON-
SORT checklist was submitted, only one paper had
complete consistency between the checklist and the pub-
lished paper. The most concerning problems centred on
items 8 and 9 (see Fig. 1). For example, a possible incon-
sistency identified regarding CONSORT item 9 (Alloca-
tion concealment mechanism – mechanism used to
implement the random allocation sequence, describing
any steps taken to conceal the sequence until interven-
tions were assigned) is the following: authors claim
through the checklist that they have reported the item;
however, we found that the paper stated “The sequence
of the test conditions was randomized for each partici-
pant by LB and KDK. A card was made for each possible
sequence and a card was picked blindly for each partici-
pant.” This statement does not make it clear how the au-
thors implemented the random allocation sequence nor
how they kept the assignment concealed. Picking a card
does not guarantee that allocation used in the analysis
has preceded treatment, nor does it allow readers to re-
produce the mechanism used to implement the random
allocation sequence.
A full summary of the evaluations for all six items
across all six papers is shown in Additional file 2. The
level of reporting inconsistencies found for every item
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among the six papers considered in the analysis is pro-
vided in Fig. 1. Illustrative examples of inconsistencies
found for each item are shown in Additional file 3.
Why could reporting inconsistencies occur?
Among the numerous potential reasons for the presence
of reporting inconsistencies, we underline two explana-
tions. Firstly, it is possible that authors are not attentive
to the requirements of CONSORT or, despite their ef-
forts to be compliant with the requirements, they are
struggling to interpret certain items or the level of detail
that is required. Examples include:
 Item 8a ‘Method used to generate the random
allocation sequence’. This item was adequately
reported in just one of the papers screened. Within
this item, there were various reasons for the
inconsistencies, including: lack of thorough and
complete reporting from the authors (see example
for this item in Additional file 3) and the
nontechnical use of the term ‘random’ (‘The study
nurse randomly opened a preformed envelope
containing the allocated treatment regimen’).
 Item 11a ‘If done, who was blinded after assignment
to interventions (for example, participants, care
providers, those assessing outcomes) and how’. The
initial phrase ‘if done’ may have caused confusion
about whether or not the authors have to report
what groups of individuals involved in the trial were
unblinded. To avoid authors not disclosing the lack
of blinding if the trial was unmasked, we suggest
that future versions of the CONSORT checklist
delete the phrase ‘if done’.
The misinterpretation of CONSORT is a major con-
cern, as it means that essential information regarding
study conduct is miscommunicated. This is particularly
relevant for item 11a, as according to PRISMA item 19
[11], when assessing the risk of bias of a study it is neces-
sary to know whether or not patients, health care pro-
viders, data collectors and outcome assessors are blinded.
Secondly, the issues described in this study might also
lie with the reviewers and editors. It is possible that they
are falsely reassured with regard to the reporting quality
of the manuscripts, merely by the presence of a com-
pleted checklist. Moreover, the fact that the reporting in-
consistencies persist throughout the editorial process
might mean that editors and reviewers are not using
reporting guidelines as a method to review manuscripts
[12] although the CONSORT explanation and elabor-
ation document suggests that: ‘Readers, peer reviewers
and editors can also use CONSORT to help them critic-
ally appraise and interpret reports of randomized
controlled trials.’
Possible solutions
In an effort to take full advantage of requiring the sub-
mission of checklists, journals should consider clarifying
their stance on whether the full checklists, or at least the
checklists’ core items should be examined by editors or
reviewers, or even by trained editorial assistants [13].
As the page numbers reported by authors in the
checklist are not updated after the peer review process
and the typesetting process, they do not correspond to
the page where the information is placed in the pub-
lished paper. Having to update the page numbers in the
checklist from original submission to published paper
could act as a checkpoint for editors or reviewers to re-
mind them to verify whether authors are appropriately
reporting the key information in the latest version of the
manuscript. An alternative solution could be to ask
authors to address the section and the paragraph where
the information corresponding to each item is reported.
This would reduce the risk of overburdening the authors
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Fig. 1 Reporting inconsistencies found for the six papers that used the appropriate CONSORT checklist
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and could potentially help deter the misconception that
these checklists are merely bureaucratic. Furthermore,
making available the updated checklist could help sys-
tematic reviewers easily and quickly find the relevant in-
formation to assess the risk of bias of the studies
included in the reviews [11].
Conclusions
Poor-quality reporting in health research critically affects
the credibility, reproducibility and generalizability of the
methods and findings of randomized trials. For these
reasons, further exploration of methods that will obligate
authors to consistently and accurately fulfil and submit
CONSORT checklists is required. Moreover, journals
should consider making clear whether the checklists
should be examined by editors, peer reviewers or a
trained editorial assistant.
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